[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine].
A new promising perspective in nuclear medicine is the use of radiolabeled antisense oligonucleotides as diagnostic markers. Especially for cancer diagnostics, a quantitative accumulation of antisense probes which are directed against abundantly expressed oncogene mRNAs seems to be reasonable. However, the development of this strategy still requires an optimization of several parameters: (i) rapid and efficient radiolabeling methods, (ii) a fast penetration of the probe into the target tissue, (iii) a fast internalization into the tumor cell, (iv) an oligonucleotide/mRNA hybrid formation with high specificity, and (v) a high stability of the hybrid against intracellular nucleases.
Hildebrandt
M
M
Universitätsklinikum Ulm, Abteilung für Nuklearmedizin, Deutschland.
Reske
S N
SN
D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics; D009857:Oncogenes; D012333:RNA, Messenger; D011877:Radionuclide Imaging / Q000379:methods*
D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger